PTC治疗 PTCT 深 沪
已收盘 10-03 16:00:00 美东时间
65.37
+2.350
+3.73%
华盛通- 最 高67.40
- 今 开63.71
- 成交量 271.88万股
- 最 低 63.29
- 昨 收 63.02
- 总市值 51.93亿
- 52周最高 67.40
- 市盈率 静 --
- 换手率 3.42%
- 52周最低 35.51
- 委 比 61.86%
- 总股本 7943.81万
- 历史最高 78.72
- 量 比 2.61
- 振 幅 6.52%
- 历史最低 4.03
- 每 手 1
- 风险率 5.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WARREN, N.J., Oct. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Sept. 28, 2025, the company approved non-statutory stock options to purchase an aggre...
10-02 04:30
Larimar Therapeutics Stock Falls After Patients Report Allergic Reaction In Pivotal Study
Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg injections of nomlabofusp self-administered or administered by a caregiver in participants with
09-29 23:20
海西新药冲击IPO，用仿制药养创新药，销售费用率较高
近期，又有一家来自福建的创新药企冲击港股IPO。 格隆汇获悉，福建海西新药创制股份有限公司（简称：海西新药）递表港交所，由华泰国际、招银国际担任联席保荐人。 与...
09-14 16:49
PTC Therapeutics Could Challenge BioMarin For Metabolic Disorder Treatment
BioMarin's Palynziq significantly lowered blood phenylalanine in teens with PKU, with nearly half reaching target levels in the Phase 3 study.
09-09 01:56
Cantor Fitzgerald Reiterates Overweight on PTC Therapeutics, Maintains $118 Price Target
Cantor Fitzgerald analyst Kristen Kluska reiterates PTC Therapeutics (NASDAQ:PTCT) with a Overweight and maintains $118 price target.
09-03 21:49
美股大行评级 | 潜在涨幅166.67%！美银证券上调Rocket Pharmaceuticals目标价至10美元，评级升至"买入"
今日重点评级关注：美银证券：上调Rocket Pharmaceuticals评级至"买入"，目标价从4美元升至10美元；花旗：维持小鹏汽车"买入"评级，目标价从29美元升至29.4美元
08-21 19:00
B of A Securities Maintains Buy on PTC Therapeutics, Lowers Price Target to $76
B of A Securities analyst Tazeen Ahmad maintains PTC Therapeutics (NASDAQ:PTCT) with a Buy and lowers the price target from $82 to $76.
08-20 20:21
PTC Therapeutics rare disease therapy rejected by FDA
PTC Therapeutics (NASDAQ:PTCT) announced on Tuesday that the U.S. FDA issued a complete response letter in response to its marketing application for vatiquinone, rejecting the small molecule drug as a...
08-19 20:42
PTC Therapeutics Receives FDA Complete Response Letter
PTC Therapeutics ( ($PTCT) ) has issued an update. On August 19, 2025, PTC Ther...
08-19 20:28
PTC Therapeutics’ Earnings Call Highlights Sephience Success
PTC Therapeutics (($PTCT)) has held its Q2 earnings call. Read on for the main ...
08-13 08:21
